Cart
sales@molnova.com
B I09
CAS No. 1607803-67-7
B I09( —— )
Catalog No. M33303 CAS No. 1607803-67-7
B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 67 | Get Quote |
|
| 5MG | 93 | Get Quote |
|
| 10MG | 155 | Get Quote |
|
| 25MG | 247 | Get Quote |
|
| 50MG | 364 | Get Quote |
|
| 100MG | 506 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameB I09
-
NoteResearch use only, not for human use.
-
Brief DescriptionB I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
-
DescriptionB I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.
-
In VitroB I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM. Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. B I09 is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells.
-
In VivoB I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorIRE1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1607803-67-7
-
Formula Weight303.31
-
Molecular FormulaC16H17NO5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 8.33 mg/mL (27.46 mM; Ultrasonic )
-
SMILESOc1ccc2c3CCNCc3c(=O)oc2c1C1OCCCO1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ranatunga S, et al. Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301.?
molnova catalog
related products
-
ACTH 22-39
ACTH (22-39) is an adrenocorticotropic hormone (ACTH) fragment and it is the 22-39 sequence of ACTH.
-
Pomalidomide-PEG3-OH
Pomalidomide-PEG3-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
-
Combretastatin A-1
Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt/β-catenin pathway, and can be used to study hepatocellular carcinoma.
